ROMA (ITALPRESS) – “The total pharmaceutical expenditure (direct purchases + contracted) in the first 9 months of 2025 stood at 18 billion and 420 million, with a split from the planned roof of 2.85 billion euros. By disposing the total expenditure in the two items forming it (expenses for direct purchases from hospitals and ASL and expenses for distribution agreed through pharmacies) it emerges that the expense for direct purchases flows its own roof of 3,38 billion euros, while the agreed expense is less than 0,47 billion compared to its roof. It is therefore not correct to address the problem of the strengthening of pharmaceutical spending by going to look for the causes in the agreed pharmaceutical expense, as instead the Dataroom of Corriere della Sera published online on February 23″. So Federfarma in a note.
“To take advantage of this paradoxical thesis, the article identifies two main causes: the new remuneration of pharmacies for the dispensation of SSN drugs and the transfer from direct to the agreement of some classes of medicines used in the treatment of diabetes – continues Federfarma –. As regards remuneration, before the reform of 2024, the system was based essentially on the percentage of the price of the drug, making an exception at European level and helping to strongly limit the availability of innovative drugs in pharmacy at the expense of citizens. The new system – which has been strongly wanted by all the governments succeeded from 2012 to today, even to align Italy to other European countries – significantly reduces the remuneration of pharmacies on the most expensive medicines and increases it on the lower price drugs, recognizing the value of the professional act of dispensation”
“The impact of the new remuneration on pharmaceutical spending has been foreseen by the Legislator, precisely quantified by the Agency for the Drug and certified by the General Reason of the State within the limits of the budget forecasts: in fact, there has not been any reinforcement of the roof of the agreed pharmaceutical expense – emphasizes the association of category -. With regard to the transfer of some medicines from direct to agreed, the AIFA data certified by MEF show that the distribution channel change of glyphlozines has resulted in a savings of €9.2 million, which on an annual basis corresponds to a savings of approximately €36.5 million. Moreover, this reclassification slowed the growth of the consumption of glyphlozine which recorded a +37.7% after the passage, in front of a +49% of the previous years. Given the strong regional differences in the consumption of medicinal products, and therefore of the relative costs, it is only the AIFA, as an independent regulator, that can provide an authoritative and reliable analysis of the impact of reclassification of drugs, and not a partial reconstruction related to dispensation in one or two regional territories”.
“Beyond the economic aspect, the transfer of these two classes of drugs has made it much easier and homogeneous to access the drug, as also demonstrates the appreciation repeatedly expressed by patient and citizen associations. In particular, this measure achieves a substantial equality of accessibility to medicinal products without distinction between territories avoiding the citizen to have to return at least twice in pharmacy, as happens instead in the dispensation on behalf of the ASL – Federfarma concludes -. The passage of these medicines in a conventional regime then improves therapeutic adherence. According to the Osmed data, only 45% of patients with diabetes regularly take drugs: approaching the place of dispensation to the residence of the chronic patient and simplifying the methods of access to the drug constitute an extraordinary opportunity to verify and improve adherence to therapy”.
-Photo IPA Agency-
(ITALPRESS).
